ReviewJournal of neurology2025
A review of the link between the lactate-GPR81 axis and mitochondrial angiopathy in MELAS based on imaging characteristics.
Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The differential diagnosis between Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) and acute ischemic stroke (AIS) is frequently confounded by the profound vascular heterogeneity inherent to MELAS, exemplified by phenomena such as the vessel flow-void sign (VFVS). This review first outlines the imaging hallmarks that distinguish MELAS from acute ischemic stroke, then interrogates the ostensible paradox between the systemic nitric oxide (NO) deficiency in MELAS and the localized vasodilation manifested as VFVS. We posit that lactate accumulation, a metabolic hallmark of the disease, is a principal yet underappreciated driver of this vascular phenotype. To address this mechanistic gap, we propose a conceptual framework centered on the G-protein-coupled lactate receptor 81 (GPR81). We hypothesize that the lactate-GPR81 signaling axis within the cerebral microvasculature constitutes a key pathway through which lactate modulates vascular smooth muscle cell phenotypic switching, angiogenesis, and microenvironmental remodeling, thereby orchestrating the unique vascular pathology of MELAS. While the precise mechanisms remain debated, we contend that a focus on mitochondrial vasculopathy is fundamental to elucidating the vascular heterogeneity in MELAS. By proposing the lactate-GPR81 axis as a central mediator, this perspective offers a refined conceptual framework to reorient future empirical investigation toward the development of diagnostic and therapeutic strategies that target this critical, albeit contested, vascular pathology.
Indexed as
Identifiers
40797122What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.